Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Lilly beset by potential Strattera imitators
Strattera poachers are besieging Eli Lilly on all sides. Sandoz, the Novartis generics unit, is challenging Lilly's patent on the hyperactivity drug, set to expire in 2017, in federal court. Sandoz is seeking a pre-emptive ruling to protect its copycat version of Strattera. This comes after Lilly filed suit against Iceland-based Actavis Group to block that company's Strattera generic. And no wonder Lilly's so protective: the drug generated $282 million for the company during the first half of 2007.
- here's the report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
